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license (http://creativestudying the pathophysiology of Alzheimer’s and related diseases. Measurement of subtle changes in
amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid
PET scans acquired at multiple sites and over time requires rigorous standardization of acquisition pro-
tocols, subject management, tracer administration, image quality control, and image processing and
analysis methods. We review critical points in the acquisition and analysis of amyloid PET, identify
ways inwhich technical factors can contribute tomeasurement variability, and suggestmethods formiti-
gating these sources of noise. Improved quantitative accuracy could reduce the sample size necessary to
detect intervention effects when amyloid PET is used as a treatment end point and allow more reliable
interpretation of change in amyloid burden and its relationship to clinical course.
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The development of noninvasive methods for detecting
amyloid plaques in human brain using positron emission to-
mography (PET) has made remarkable contributions to our
understanding of the pathophysiology of Alzheimer’s dis-
ease (AD) and related conditions, and it has facilitated
more accurate and confident diagnosis. PET imaging witheimer’s Association. This is an open access article under the CC BY-NC-ND
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has been widely adopted as a means of identifying and
following amyloid burden by pharmaceutical companies
conducting interventional trials in AD, academic research
centers, and consortia studying the evolution of AD. In
this setting, it has facilitated testing of a number of candidate
disease-modifying treatments.
Clinical use of amyloid PET commonly relies on visual
interpretation (reading) of scans, in which the signal inten-
sity of “target-rich” brain regions such as frontal cortex is
contrasted to that of “target-poor” regions such as subcor-
tical white matter. Visual reads can be used for assessing
the likelihood of significant fibrillar Ab burden in the brain
by correlating imaging findings with postmortem plaque
density. The standardization and qualification of visual
interpretation has been a major undertaking and is
described elsewhere [1,2]. Here, we will focus on the use
of quantitative measurement of amyloid PET, which
requires a number of practices that are not necessary for
visual interpretation.
Quantitative analysis is necessary for longitudinal obser-
vational studies and intervention trials when change in amy-
loid burden measured by PET serves as a treatment end
point. Treatments intended to remove Ab may have modest
effects on the amyloid PET signal that are not apparent by
visual comparison of scans. Detecting the effect of drugs de-
signed to modify Ab deposition, such as secretase inhibitors,
will require identifying treatment effects against the back-
ground rate of signal change, which may be slight and
affected by genetic risk factors and age. Testing for PET
signal differences in studies including placebo and multiple
active dose arms requires averaging across subject responses
in each treatment group. Phase 2 and 3 AD trials are typi-
cally large, requiring participation by multiple imaging cen-
ters, which adds the complexity of using different scanner
models that may use different image construction methods.
Site practices commonly differ with regard to dose calibra-
tion and tracer administration, scanner and analytic equip-
ment quality control (QC), and subject management after
dose administration and during the scan. These factors can
increase measurement noise, undermining the quality of
the image data and the reliability of the results of the ana-
lyses, and consequently reducing the power to detect treat-
ment differences. The impact of differences between sites,
scanners, acquisition protocols, and subject management
on image data quality is not unique to quantitative amyloid
PET. These topics and more have been the focus for the
Quantitative Imaging Biomarkers Alliance (QIBA) in the
Radiological Society of North America and the European
Association of Nuclear Medicine (EANM) to improve the
value and reliability of quantitative fluorodeoxyglucose
(FDG) PET/computed tomography (CT) for oncology trials
[3,4]. Our goal was to bring these issues to the attention of
clinical and pharmaceutical researchers considering
quantitative amyloid PET as an end point so that they can
be considered when acquiring and analyzing the data. Toillustrate the point, inspection of individual trajectories of
the 11C-PiB PET cortical signals from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI), one of the first
efforts to use the method at multiple sites over time with a
standard acquisition protocol [5], reveals most subjects hav-
ing modest differences from scan to scan (Fig. 1). Neverthe-
less, several longitudinal changes follow patterns that are
biologically implausible and exceed the 3% to 10% vari-
ability expected from test-retest studies of 11C-PiB reported
from single sites [6,7]. An important concept in quantitative
amyloid PET that will underlie discussion in this article is
that of amyloid positivity. In the most widely used method,
cortical amyloid signal (reflecting amyloid plaque
deposition) is related to a reference region that is believed
not to accumulate amyloid (reference), producing a
measurement known as the standard uptake value ratio
(SUVR) and is further described later.
In this article, we will consider the impact of two sources
of measurement variability: biological and technical. Tech-
nical sources can be further divided into factors occurring
at the PET center (scan acquisition and scanner instrumenta-
tion) and post–image acquisition factors (image processing
and data analysis). Beyond describing these factors and as-
sessing their impact, we aim to identify ways to optimize
quantitative amyloid PET imaging for multisite trials, to pro-
vide guidance for mitigating the most common sources of
error, and to support the qualification of amyloid PET imag-
ing as a biomarker in interventional trials.2. Biological factors
Biological factors fall into two groups: factors that
generate differences between subjects and factors affecting
measurements within subjects during or between scans.
The former group is relevant for understanding disease
biology and progression, and it includes variables that can
be considered when enrolling subjects for trials or stratifying
analyses. Understanding the second group is critical for reli-
able measurement over the course of longitudinal studies.2.1. Between-subject factors
Aging is a major risk factor for the development of AD
reflecting the many years over which the pathophysiology
evolves including accumulation of insoluble amyloid de-
posits. Amyloid plaques are first noted at autopsy between
the fourth and fifth decade of life [8]. Longitudinal and
cross-sectional amyloid PET studies that have included
young and middle-aged healthy adults have identified
subjects with significant cortical signal somewhat later,
beginning in the sixth decade of life [9,10]. The earlier
appearance at autopsy likely reflects the years of
accumulation of dense amyloid plaques necessary to
achieve a minimum density and binding volume for signal
detection with PET, as well as the threshold selected for
amyloid positivity. The incidence of healthy adults
Fig. 1. Longitudinal changes in 11C-PiB SUVR in ADNI-1. The change in cortical average SUVr from the first 11C-PiB scan is plotted for each of 83 subjects
fromADNI-1 (20 NL, 45MCI, and 18 AD based on diagnosis at the time of first 11C-PiB scan). Unique colors and symbols have been assigned to each subject in
the three diagnostic groups to facilitate following individual trajectories. Cortical average was calculated using the mean of values for anterior cingulate, frontal
cortex, lateral temporal cortex, parietal cortex, and precuneus cortex, normalized to gray cerebellum (source: adni_pibpetsuvr_2011_07_04). Despite a small
mean change for each group and each interval relative to baseline (0.02–0.06, 1%–4%), variance is high (range20.27 to 0.52,213% to 29%) and trajectories
change direction for several subjects. For up-to-date information on ADNI and how to access ADNI data, see www.adni-info.org.
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by Washington University, which included subjects from
45 to 86 years old, was estimated to be 3% per year, and
the risk of conversion to amyloid positive appeared to rise
with advancing age [9]. The annual incidence rate of
becoming PiB positive in a recent study from the Mayo
Clinic, evaluating subjects on average 10 years older than
those evaluated by Washington University, was estimated
to be 13% per year [11]. The prevalence of subjects who
were florbetapir positive in their eighth decade in the study
by Fleisher et al. [10] was 40%, double the prevalence of
subjects in their seventh decade. Aging is also associated
with susceptibility to genetic risk factors and emergence of
other risk factors for AD such as cerebrovascular disease.
How these other factors interact with measurement of amy-
loid burden on PET is considered later.
Genetic background can strongly influence amyloid
burden. The amyloid precursor protein (APP) and presenilin
mutations in families with dominantly inherited early-onset
AD, and the overexpression of APP resulting from trisomy
21 in Down syndrome, are associated with increased prote-
olysis of APP (APP mutations) or reduced production of
shorter, more soluble protein fragments in favor of longer,
more amyloidogenic fragments (presenilin mutations). Asin sporadic AD, significant brain amyloid burden appears
years before symptoms of dementia [12,13] although
accumulation of amyloid deposits may start earlier than in
sporadic AD. The location of the mutation may influence
the timing, rate, and location of accumulation (reviewed in
the study by Karran et al. [14]). Amyloid PET signal in stria-
tal regions has been reported to be relatively higher early in
the disease course of familial AD compared with that in the
sporadic AD [12,15]. Carrying one or more APOE ε4 alleles
is the major risk gene associated with sporadic AD and
lowers the age of onset compared with noncarriers [16,17].
Cross-sectional amyloid PET imaging studies including
healthy elders, subjects with mild cognitive impairment
(MCI), and subjects with probable AD have reported a
higher frequency of “positive” scans in APOE ε4 carriers
[9,18,19]. Modeling of florbetapir cortical SUVRs by age
indicated that significant amyloid burden could occur as
early as 58 years in APOE ε4 carriers, 20 years before the
first noncarrier reached threshold in their sample [20], sug-
gesting that carriers begin accumulating amyloid earlier
than noncarriers. An impact on the rate of deposition is sug-
gested by a longitudinal study with PiB imaging in well-
characterized subjects with probable AD, which reported a
gene-dose effect on change in cortical PiB signal over 2 years
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homozygotes, and a change of signal might also occur as a
consequence of longer opportunity for posttranslational
modification of plaques if deposition begins earlier in car-
riers, resulting in greater binding capacity for PiB. Cumula-
tively, amyloid PET data stratified by carrier status are
consistent with the idea that the APOE ε4 allele can accel-
erate the onset of AD, although carrier status does not appear
to affect duration of disease [22].
Gender is another possible genetic contributor to amyloid
deposition. An age- and gender-dependent interaction of
APOE ε4 and plaque density has been reported at autopsy
[23] although to date gender effects on amyloid burden
and change have not been identified. Vascular disease is a
common antecedent to cognitive impairment and dementia
[24], and cerebrovascular pathology has been observed
more frequently at autopsy in AD than other neurodegener-
ative disorders. Cerebrovascular disease has been proposed
to increase the risk of dementia in AD, especially in early
stages of disease [25]. Unmedicated hypertension was found
to be correlated with higher amyloid burden measured by
florbetapir in cognitively healthy elderly subjects carrying
one or more APOE ε4 alleles [26]. Arterial stiffness was
explored as a risk factor for brain amyloid burden and
change over 2 years in a sample of nondemented elderly us-
ing 11C-PiB PET. Peripheral versus central arterial stiffness
contributed independently to amyloid burden and change
[27]. No interaction was seen with APOE ε4 carrier status
although these subjects were on average 10 years older
than those in the study testing the role of hypertension, sug-
gesting an interaction between vascular and genetic risk fac-
tors, so that the impact of vascular factors on brain amyloid
PET measures may be age dependent.
A particular vascular pathology that occurs in AD is cere-
bral amyloid angiopathy (CAA). Many subjects with AD
develop significant CAA in addition to parenchymal pla-
ques. Current tracers do not discriminate the two types of
amyloid deposition, and nondemented subjects with prob-
able CAA have been reported to manifest significant brain
amyloid burden with 11C-PiB PET, notably having higher
signal in the occipital cortex relative to other cortical regions
compared with AD subjects [28]. The extent to which CAA
contributes to amyloid signal poses a problem for interpreta-
tion of signal in intervention trials, for example, testing
whether amyloid-targeting treatments affect vascular amy-
loid deposits or whether CAA load could predict the emer-
gence of amyloid-related imaging abnormalities during
treatment [29,30].
Demonstrating an effect on amyloid PET signal may
depend on the type of amyloid deposited. The in vivo
cortical signal detected with current tracers has been linked
to dense plaque burden postmortem both quantitatively [31]
and semiquantitatively [32]. Indeed, one subject has been re-
ported in whom a 11C-PiB PET scan acquired 3 years before
death failed to detect significant diffuse amyloid burden
observed at autopsy, in the setting of low cerebrospinal fluid(CSF) Ab42 and mild dementia of the AD type [33]. On the
other hand, in vivo PiB signal has been reported in associa-
tion with postmortem findings of high diffuse plaque burden
[34]. Moreover, retention of PET tracer is seen in the stria-
tum early in the course of disease in familial AD due to
certain mutations, and this region is known to harbor large
numbers of diffuse plaques [35,36]. In addition, cerebellar
cortex manifests large numbers of diffuse plaques
postmortem in late-stage disease and in some types of famil-
ial AD, leading to some concern about relying on this area as
a reference region [37].
Lifetime education and occupational achievement can
modulate the onset of cognitive decline and AD dementia
[38]. Higher education appears to delay clinical impairment
in the face of disease progression, potentially by calling on
neural reserve or other compensatory mechanisms [39].
Whether cognitive activity could mitigate disease progres-
sion has been explored in a cross-sectional study of amyloid
burden in healthy elderly subjects. Those subjects with the
highest level of cognitive engagement had a significantly
lower cortical amyloid burden, measured with 11C-PiB,
than those with lower levels of engagement [40].2.2. Within-subject factors
A limited number of biological factors may contribute to
within-subject amyloid PET signal variability. These can be
broadly divided into factors that can affect the tissue signal
and factors that can affect tracer delivery. Progressive
cortical atrophy has the potential to alter the tissue signal
over the course of AD trials, as loss of tissue volume can
result in a drop in the amyloid signal in the absence of
change in amyloid burden. This phenomenon, termed partial
volume effect (PVE), can alter serial PET measurements if
the regions of interest (ROIs) are defined on the baseline
scan and are then applied to all other subsequent scans.
How this can be addressed by partial volume correction is
discussed later. Possible reduction of the amyloid PET signal
by a drug treatment that competes with tracer binding also
needs to be considered. The binding site(s) for thioflavin-
and stilbene-derivative amyloid tracers is not fully under-
stood although binding pockets are hypothesized to occur
across strands of Ab within the b-sheeted fibrils [41]. In
the phase 2 study testing the effect of the amyloid-
targeting monoclonal antibody bapineuzumab on brain
amyloid using 11C-PiB PET, competition studies using anti-
body concentrations well in excess of predicted tissue levels
showed no difference in binding of 3H-PiB to Ab fibrils [42].
The epitope for bapineuzumab is the amine terminus of Ab;
whether treatments targeting other regions of amyloid pep-
tide or fibril aggregation compete with amyloid PET ligand
binding may need to be confirmed. Interference with drug
metabolism, which is frequently found in pharmacology
and test drug exposures, can change rapidly over the course
of a clinical trial if concomitant medications that are meta-
bolic enzyme inducers or inhibitors are introduced. PET
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of metabolic clearance can significantly affect the “input
function” of the tracer or radiolabeled metabolites [43].
Currently available amyloid PET ligands are metabolized
very rapidly (eg, see the article byWong et al. [44]).Whether
metabolism of PiB is susceptible to interference by inhibi-
tion of metabolism has been tested. Metabolism occurs via
several metabolic pathways rendering clearance of PiB
less susceptible to inhibition by a particular metabolic
enzyme inhibitor [45]. Whether other PET ligands are simi-
larly cleared via multiple pathways and whether alteration in
metabolic clearance could occur as a result of drug interac-
tion or liver disease have not been reported. Delivery to and
clearance of the tracer from brain is highly dependent on
blood flow, which differs across tissue types [46] and is
significantly reduced in AD, particularly in gray matter re-
gions known to be susceptible to neurodegeneration and at-
rophy [47]. Unlike with FDG PET, a subject’s mental state is
not thought to affect amyloid PET results although testing
for effects of major differences in attention and arousal,
such as sedation, has not been conducted in humans. The
critical dependence on blood flow for delivery of the tracer
to the brain underlies the need for strict control over tracer
uptake and emission data acquisition and different ap-
proaches to data collection outlined later.3. Acquisition factors
PET image acquisition involves a series of technical pro-
cesses, and a thorough description of how images are gener-
ated is beyond the scope of this review. Nonetheless, a brief
summary may help provide an orientation to how acquisition
factors influence quantitative analysis of amyloid PET.
Further information on PET data acquisition can be found
in recent textbooks [48].
The basis of PET signal generation lies in a g photon, two
of which are produced by mutual annihilation after a posi-
tron emitted from the PET isotope collides with a neigh-
boring electron. The photons travel away from the
annihilation site in the opposite directions and can be de-
tected by a pair of detectors located opposite one another
in the PET camera. This defines what is called a “line of
response” (LOR) through the part of the body being imaged
and indicates that a PET radioisotope was somewhere along
the line. Gamma photons continue to be produced from the
radiolabeled tracer in the tissue generating LORs in all direc-
tions. Detectors will also record g photons that have rico-
cheted off their original LOR after colliding with electrons
during their transit away from positron annihilation (scatter)
and other stray events. Contrast in the image depends on
more signals emanating from the radiotracer bound to the
target of interest than radiotracer retained in target-poor
areas or from radiolabeled metabolites and reducing noise
such as scattered counts. The first form of data is the
recording of the detected events in each LOR. These data
are represented in a sinogram according to the spatial orien-tation of the LORs to facilitate subsequent computations.
Emission data can be collected in two or three dimensions
(2D or 3D); the latter has greater sensitivity and is available
on most modern PET scanners. Data can be recorded contin-
uously (list mode) or over discrete intervals resulting in
“frames” (from time frames) of data. Collection can begin
when the tracer is injected and followed for an extended
period to allow full characterization and modeling of tracer
kinetics (dynamic scans) and is more fully described later,
although for diagnostic scans, collection usually begins
long after tracer injection. Data are typically collected
over 5 minute periods for up to 10 or 20 minutes to record
enough counts resulting in two to four frames of PET data
(static scans). These frames can be inspected separately for
evidence of movement during the scan, and acceptable
frames are then combined to form the complete emission
data file. These emission data are corrected for signal loss
or attenuation by bone and other tissues calculated from a
transmission scan: a scan generated by an external positron
source such as a rod containing 68Ge germanium rotated
around the bore of PET-only cameras, or more commonly
by a scan generated by x-ray in PET/CT cameras. The emis-
sion scan is also corrected for noise resulting from scattered
and random counts (i.e., counts that are not representative of
paired photons from a single annihilation or “true events”),
signals missed by the detectors when they are busy recording
counts (dead time), and corrections for sensitivity differ-
ences between the detectors (obtained from “normalization”
scans performed as part of camera QC). The corrected emis-
sion data are then reconstructed to form an image that is a
quantitative estimate of the spatial distribution of the radio-
isotope. All these corrections occur on the sinogram, and ac-
curate image reconstruction is critically important for
quantification purposes. Reconstruction occurs by using
either filtered back projection (FBP) or iterative algorithms
such as ordered-subsets expectation maximization
(OSEM). Each of these processing steps can involve
different assumptions and algorithms unique to the scanner
type, and how these can impact measurements in amyloid
PET is considered later.3.1. Scan acquisition
Although the measure of interest in amyloid PET is amy-
loid burden, the PET signal is a composite of radioactivity
from tracer concentrations in multiple “compartments”:
the blood into which the tracer was infused and from which
it will be cleared, a “free” tissue compartment in which the
tracer has crossed the blood-brain barrier but is not bound,
the specific amyloid-binding compartment of interest, and
a nonspecific binding compartment [49]. Two primary ap-
proaches are available for scan acquisition, each with advan-
tages and limitations.
The “gold standard” for quantitative PET image analysis
is full kinetic modeling with arterial blood sampling, in
which the scan is collected as a series of contiguous time
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rium is reached. The time course of radioactivity signal at
any point within the brain forms a “time-activity curve.”
This includes an initial period of a fewminutes during which
the signal largely reflects tracer influx from plasma into tis-
sue, highly correlated with regional cerebral blood flow rate
[50,51]. A nonequilibrium stage follows during which
specific binding approaches a plateau, followed by a
period of relative equilibrium. The time to reach
equilibrium varies with the particular tracer, the region of
accumulation, and amyloid load [44,52,53]. With the
plasma input concentration known, a set of differential
equations characterizing the tracer influx and efflux from
each compartment are solved to achieve a best fit to the
acquired curve. To eliminate the discomfort and logistical
issues associated with arterial blood sampling, simplified
models have been developed that use ratios of time-
activity curves in target regions to those in a region of tissue
in which specific binding is negligible (reference region)
without requiring blood data. Amyloid burden is expressed
as the quantity distribution volume ratio (DVR) [9,49].
Although some models have demonstrated better
robustness, noise, and bias characteristics than others [54],
by using information from the time of injection until tracer
activity in tissue approaches relative equilibrium, all are
able to dissociate PET signal contributions from blood
flow and rate of tracer clearance. This can define and thereby
minimize erroneous impact of these factors on amyloid
burden estimates.
Although dynamic scanning is the gold standard for quan-
titative measurements, as we noted previously, the most
widely used approach to amyloid PET is the use of the
average activity measured over late time frame, “pseudo-
equilibrium” phase scans, in which a ratio of activity in tis-
sue regions known to accumulate high amyloid burden to
that in a reference region with presumably no dense fibrillar
amyloid (SUVR) is used to estimate amyloid burden. This
minimizes the time that the patient must spend in the scan-
ner, reduces acquisition and analysis complexity, and does
not require a scanner capable of acquiring dynamic data
and is by far the most practical. A high correlation has
been established between SUVR and DVR measures, with
both resulting in significant discrimination between AD pa-
tients and normal controls [44,53,55] and in similar rates of
amyloid accumulation in longitudinal studies [21,56]. A
limitation is that the SUVR approach, which does not use
early frame information, does not distinguish contributions
of blood flow and clearance. One effect is that SUVRs
may overestimate amyloid burden, a bias that increases
with later time windows, because of a lack of true
equilibrium between plasma and tissue as the tracer clears
from plasma [57]. If the tracer delivery and clearance is
similar within a subject group, this bias should result in a
simple scalar difference in empirically generated thresholds
for SUVR versus DVR values [58]. However, differences
across subject groups and longitudinal changes in bloodflow and/or clearance within subjects are more difficult to
address. A study in AD, MCI, and healthy controls using
11C-PiB showed that although longitudinal reductions in
late frame SUVR values were observed in AD subjects, there
was little or no change when dynamic modeling was used.
The decline in SUVR values in AD subjects paralleled a
decrease in the uptake rate of the tracer from blood into
brain: detected by the “k1” rate constant derived from ki-
netic modeling but not from SUVR calculations. Thus,
apparent decreases in SUVR values may be driven by reduc-
tions in cerebral blood flow in AD [58], which is a consider-
ation for longitudinal studies following disease progression.
In the following discussion, we assume SUVR will be used
as the quantitative measure for amyloid PET studies.
Other approaches have been proposed with the goal of
improving accuracy. These include a bolus plus infusion
approach that provides true equilibrium between plasma
and tissue in late time frames [57] but presents implementa-
tion challenges and a regional equilibrium correction that re-
duces the bias in late time frame estimations [59].
Regardless of the acquisition and analysis approach used,
however, amyloid burden measurement can only be valid
if the raw PET signal is without artifact.
3.1.1. Radiotracer characteristics
Several radioligands have been developed for imaging of
fibrillar amyloid in the brain. The chemical structure and
standard late time frame acquisition periods for 11C-PiB
[55] and the 18F fluorine–labeled tracers florbetaben
[18,60], florbetapir [61], flutemetamol [53,62], and
NAV4694 [63,64] are provided in Table 1. The use of 11C
carbon as the radiolabel, with a 20-minute half-life versus
18F fluorine with a half-life of 110 minutes makes a huge dif-
ference for multisite trials. Radiolabeling with 11C tracers
requires on-site production, whereas radiolabeling with 18F
allows for regional distribution and the potential for scan-
ning more than one subject per tracer production driving
the adoption of 18F tracers for intervention studies. Preclin-
ical profiling and autopsy studies have provided evidence
that cerebral cortical retention of these tracers in vivo corre-
lates with the burden of neuritic plaque load seen in the same
brain regions postmortem [31,32,34] and at biopsy [65].
They rapidly enter the brain by passive diffusion across the
blood-brain barrier, and the first-pass extraction fraction is
likely high, resulting in delivery being as highly dependent
on blood flow as described previously. An important source
of variability in amyloid measurement comes from differ-
ences between tracers in white tissue residence time and up-
take in gray matter. High-affinity binding of the tracer to
fibrillar amyloid results in much slower clearance from
gray matter bearing amyloid plaque. Clearance from white
matter depends on the absence of high-affinity binding tar-
gets such as amyloid plaque but also the degree to which
nonspecific low-affinity binding occurs; for example, more
lipophilic tracers can have a larger distribution volume in
highly lipid white matter. White matter may also have
Table 1
Amyloid PET tracers currently available for research or commercial use
Tracer Structure Recommended dose
Recommended acquisition time post injection (p.i.) of tracer
from the literature/allowable range in the FDA label
11C-PIB 500 MBq 50–70 min p.i.
Florbetaben 300 MBq 90–110 min/15–20 min scan beginning 45–130 min p.i.
Florbetapir 370 MBq 50–70 min/10 min scan beginning 30–50 min p.i.
Flutemetamol 185 MBq 90–110 min/20 min scan beginning 901 min p.i.
NAV4694 200 MBq 40–70 min p.i.
Abbreviations: PET, positron emission tomography; FDA, Food and Drug Administration.
NOTE. Subtle differences in the chemical structure can alter the clearance rate from the brain, for example the introduction of a fluorine atom results in
flutemetamol being more slowly cleared than PiB while introduction of a single nitrogen atom results in florbetapir being more rapidly cleared than florbetaben.
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11C-PiB signal reductions associated with white matter dis-
ease [66]. As a consequence of their unique physical and
chemical characteristics, gray versus white matter uptake
and retention varies between tracers [67]. For those tracers
that have been compared “head to head,” the retention in
cerebellar gray matter is highest for 11C-PiB, followed by
flutemetamol and then florbetapir, whereas white matter
retention is highest for flutemetamol followed by 11C-PiB
and then florbetapir [68]. Retention in gray and white matter
has been reported to be equivalent between 11C-PiB and
NAV4694 [64]. Whether differences in tissue retention
among the tracers translate into material differences in de-
tecting presence or change of an amyloid signal has not
been determined. Approaches to reconcile these differences
have been proposed [68] and are further discussed in the
analysis section.
Independent of the tracer selected, variability in tracer
composition and activity can impact measured signal, and
QC is therefore essential. Generation of a good imaging
signal depends on production of the radiotracer with suffi-
cient radioactivity, purity, and specific activity, and a number
of specifications need to be met to ensure the safety and reli-
ability of the dose. In the United States, the guidance for pro-
duction of marketed PET radiotracers is the PET Drugs
Current Good Manufacturing Practice 21 CFR Part 212
[69]. Investigational radiotracers produced under an Investi-
gational New Drug application can follow either Part 212 or
United States Pharmacopeia Chapter,823. [70]. There are
similar guidance documents for production of radiopharma-
ceuticals in the European Union [71,72]. Trial sponsors may
need to ensure these standards are met during the trialthrough expert review of the production records and
quality assurance checks. Failure to meet these standards
can result in loss of authorization to release the tracer for
clinical studies until the deficiencies have been corrected,
resulting in a loss or delay in getting scans.
3.1.2. Patient motion
Variability due to patient motion is likely one of the
largest contributing factors to measurement noise in amyloid
PET studies. There are two components to motion-induced
error. First, mismatch between the PET transmission or CT
attenuation and emission data can induce attenuation-
correction artifacts usually seen near the outer boundaries
of the brain. The attenuation properties of the head are
mostly uniform, so some types of rotational motion often
do not dramatically affect the result of attenuation correc-
tion. Translations can be more troublesome. Quantification
errors in average pixel counts for cortical ROIs have been
estimated to be 10% for translations of 5 mm and .20%
to 40% for translations .10 mm [73]. An example of a
motion-induced attenuation-correction artifact is seen in
Fig. 2.
Second, motion during the emission scan itself will result
in misaligned or blurry images so that the brain tissue
sampled in a ROI at the early portion of the acquisition
will not correspond to tissue sampled during later phases
of the scan. Anecdotally, the motion seen between dynamic
5-minute time frames in typical amyloid scans from the
ADNI study ranges from translations and rotations of
,0.5 mm and 0.5, respectively, in well-controlled subjects,
to5 mm translation and 5 rotation in more difficult cases.
These are motion estimates relative to the center of the
Fig. 2. Subject motion between acquisition frames. Examples of a PET/CT scan with significant motion and artifacts due to attenuation correction. Fused data
set (top) shows moderate PET/CT misregistration already apparent during the first 5-minute frame (left column), and severe errors by the fourth frame (right
column). In this case (middle row), the correction biases are visually evident even after motion correction by registering all time frames to the first (bottom row),
the attenuation-correction error can induce large differences in quantification, as demonstrated by the visible difference in signal on the right and left sides of the
brain and reflected in the ratios of regional uptake in simple circular ROIs on the bottom of the images.
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could be considerably higher, and variability in non-ADNI
studies could also be greater. Qualitatively, one can infer
that because ROIs are usually specified on thin gray matter
regions and because uptake differences between gray and
white matter can be large, uncompensated motion error of
this extent could add significantly to measurement noise.
Few studies of this effect have been published. One from
the Japanese Alzheimer’s Disease Initiative reported
changes in ROI values in the cortex of.10% due to motion
correction in the severest cases [74] although the frequency
and impact of more typical movements during scans are not
well understood.
Methods to combat motion start with good subject man-
agement before the scan. It is essential for site technical staff
to be aware of appropriate placement in the scanner and helpsubjects get into as comfortable a position as possible before
the start of the scan to minimize movement and emphasize
the importance of remaining as still as possible during acqui-
sition. Multiple methods including thermoplastic masks,
adjustable pillows, applying straps across the forehead,
and tape across the forehead and chin are used by sites.
There has been no standardization or systematic comparison
of the efficacy of these methods. Minor movements that
occur during dynamic scans can be managed by dividing
the acquisition into separate short time frames
(5 minutes) that may be retrospectively realigned or
omitted from the analysis [5]. Monitoring of subject motion
during image acquisition is also important, at a minimum us-
ing visual observation and noting if excessive motion occurs
to provide information during image QC. Automated sys-
tems for motion detection and correction have been
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are not typically used in clinical trials. Severe motion that in-
duces attenuation-correction artifacts is difficult to address
but image QC should attempt to identify such cases as
described in the analysis section.
3.1.3. Variability due to uptake and scan time differences
Although late-phase imaging captures the brain uptake
characteristics in a state of approximate equilibrium, vari-
ances in the emission start time after tracer injection or in
the length of scanning time can introduce variability in
SUVRs. Emission start time is frequently delayed from a
specified target time because of difficulties while positioning
patients or simply because of inattentiveness at the imaging
site. A significantly delayed start time can also occur in cases
where same-day rescans are required because of technical is-
sues in the first attempt at a scan. Differences in the length of
scanning time can occur if time frames are omitted because
of motion or if the imaging protocol in a follow-up scan was
not identical to baseline settings. As an example of potential
differences in SUVR values due to timing differences, Nelis-
sen et al. [53] showed a progressive increase from about 2.0
to 2.5 in mean frontal cortex SUVR values computed in 5-
minute intervals between 85 and 170 minutes, representing
a 25% difference. Similar, but more subtle, effects are seen
qualitatively in increasing the scan lengths from 5 to 20 mi-
nutes. Therefore, it is important to match imaging times for
individual subjects’ baseline and follow-up visits to avoid
unnecessary measurement variability. If a delay in start
time occurs at baseline, then this should be documented as
the target start time for follow-up visits. The standard
suggested by the QIBA for follow-up FDG SUV measure-
ments is 110/25 minutes of the target time [3]. A similar
time window appears suitable for longitudinal amyloid
studies. Practical experience shows that with proper training,
most sites can comply with targeted start times to within
65 minutes.4. Instrumentation factors
4.1. Spatial resolution effects
Native spatial resolutions of scanners range from just
over 2-mm full-width half maximum (FWHM) for research
scanners such as the Siemens ECAT HRRT to .7-mm
FWHM for older, but still commonly used PET scanners.
In practice, postreconstruction Gaussian filtering further re-
duces image resolution to 7- to 12-mm FWHM [75]. This in-
troduces a PVE, where pixel values from a region are blurred
into and combined with those from neighboring regions. The
phenomenon is fairly easy to describe for “hot spot imaging”
typical of tumor quantification, where a recovery coefficient
can be defined as the ratio of the observed activity concentra-
tion to the true concentration. Typically, the recovery coeffi-
cient is ,100% for objects ,30 mm in size [76]. The PVE
for amyloid images is more difficult to describe. White mat-ter tracer uptake is nonspecific and has roughly the same ac-
tivity in normal and diseased subjects for a given tracer. As
noted previously, gray matter retention is lower than white
matter uptake for several currently available tracers in re-
gions devoid of amyloid and is approximately equal or
greater than white matter uptake in amyloid-positive re-
gions. The PVE tends to blur high activity from white matter
into gray matter for normal subjects (thereby increasing gray
matter SUVR values), while having less of an effect for
diseased subjects because of the relative uniformity of the
uptake in gray and white matter. Similarly, PVE can blur
low activity from CSF, which increases in volume surround-
ing gray matter as atrophy occurs. Therefore, the PVE at
different spatial resolutions causes different effects for
normal compared with diseased subjects. An estimated
27% to 5% shift in SUVR values has been estimated for dif-
ferences in spatial resolution of 9-mm FWHM [77].
Joshi et al. [78] proposed a method for spatial resolution
compensation based on calibrated Hoffman phantom scan
data acquired at all imaging sites in a clinical trial. This “res-
olution matching” approach smooths all data to the effective
resolution of the lowest resolution scanner in the study. The
technique was adopted by the ADNI study, where all images
were smoothed to an effective resolution of 8-mm FWHM
[79]. This approach has intuitive advantages for cross-
sectional quantitative measurements and qualitative visual
reads used for enrollment criteria. All data appear much
more uniform to the readers or to the quantitative method.
However, it has a disadvantage that potentially useful
high-resolution signals from the best scanners in the study
are smoothed away. This can be mitigated by specifying
minimum scanner performance standards for a site to be
qualified to participate. Moreover, reconciliation of resolu-
tion differences does not address what the authors identify
as “low-frequency” noise sources such as the scatter correc-
tion methods used by different scanners. The value of spatial
smoothing for longitudinal studies where within-subject
change is the primary end point is debatable because the
nonspecific activity in the white matter of each subject is
believed to remain stable during treatment, so the spillover
of activity from the white matter may remain the same be-
tween baseline and follow-up. If this is the case, the PVE
may not significantly contribute to change from baseline in
SUVR values.
Partial volume correction is another potential method for
dealing with variability due to the PVE [80–83]. Partial
volume correction methods attempt to recover the true
value of the PET signal by estimating and adjusting for
spillover contributions from neighboring white, CSF, or
other gray matter tissue. Some techniques use only the
PET image information and knowledge of the scanner’s
resolution, whereas other methods also make use of the
structural gray, white, and CSF information available from
the subject’s corresponding magnetic resonance image
(MRI) [84]. In support of PVE correction, its application
was found to increase the accuracy of SUVR measurement
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ering up to 56% of lost signal due to PVEs and increasing
group discrimination [82]. In a separate study, signal recov-
ery ranged from 20% to 40% and cross-sectional discrimina-
tion between normal and AD groups was increased despite
increased variance [83]. In both cases, the researchers
strongly recommended incorporation of PVE correction
for clinical studies. However, other studies have not found
a difference when correcting for PVEs [85] or have found
that increased variance due to not consistently acquiring
MRIs on the same scanner over the course of a study offsets
benefits of increased accuracy [56]. Increased variability is
of particular concern in longitudinal studies, where accumu-
lation rates and measurable changes are very small.
Although a consensus has not been reached on when and
which correction to use, there is agreement that PVE correc-
tion is highly method dependent and that its use must be
applied consistently and with caution, including recognition
that positivity threshold values will change with the method
applied and that reference MRIs must be acquired on the
same scanner to be reliable when usingMRI-based PVE cor-
rections.4.2. Attenuation correction
Most PET scanners currently available to clinical trials
are integrated PET/CT systems, yet it is still common for a
multicenter study to also include PET-only systems. Naka-
moto et al. [86] compared quantitative differences between
CT and germanium-based (for PET-only systems) attenua-
tion correction in various organs including the brain and
found increases of about 5% in both the temporal lobe and
cerebellum for the CT-based method. Therefore, it is recom-
mended to scan the subject on the same scanner throughout
the study and not to interchangeably use a PET/CTand PET-
only (or PET/MRI) system on baseline and follow-up scans
of the same subject. Direct comparisons of the effect of
different attenuation correction methods on amyloid
SUVR quantities have not been reported in the literature.
Another aspect of CT-based attenuation correction that
may have a small effect on quantification is the CT settings
such as tube voltage, tube current, slice thickness, and recon-
struction kernel. Although in principle, diagnostic-quality
CT scans using high tube current and voltages should pro-
duce attenuation-corrected PET data with less noise than
with low-dose CT protocols, phantom studies have shown
that differences compared with low-dose CT parameters
yield at most a 2% variation to PET noise [87,88].
Therefore, to minimize radiation exposure, a low-dose CT
scan is suitable for amyloid studies with a tube voltage of
approximately 120 kVp, a tube current of 10 to 30 mA,
and slice thickness approximately the same as the native
PET slice thickness (1.22–4.25 mm depending on the scan-
ner) [87,88]. To minimize variability, the same CT settings
should be used for baseline and follow-up visits, and it is rec-ommended to set up all PET/CT scanners in the study with
similar CT parameters.
More recently, attenuation techniques are becoming
available that use mathematical modeling instead of data
sets acquired from CT or positron emission sources. The
Chang algorithm [89] is one attenuation modeling method,
and many different analytical attenuation correction
methods have been proposed for PET/MRI systems.
Because of differences in the cerebellar regions compared
with CT methods for the mathematical techniques [90] and
for PET/MRI methods [91], these two attenuation correction
methods need to be validated against CT and external posi-
tron source methods before use in amyloid quantitative ana-
lyses. Attenuation correction for PET/MRI is a highly
dynamic area of research and may be highly vendor specific.
Likewise, the scatter correction techniques used by PET/CT
and PET/MRI differ. Cumulatively, the differences in atten-
uation and scatter correction in current generation PET/MRI
platforms could introduce large quantitative differences rela-
tive to measurements with PET and PET/CT systems.
Further validation of PET/MRI is needed before it can be
recommended in quantitative amyloid PET multicenter
studies.4.3. Acquisition mode, scatter correction
Selections of 3D versus 2D acquisition modes and scatter
correction are interrelated factors in the acquisition process.
PET data may be collected in the 3D mode using coinci-
dence detection between all rings or 2D mode where coinci-
dence detection is only between nearby detector rings. A few
scanners are only capable of 2D acquisition, but most mod-
ern scanners operate only in 3Dmode for brain imaging. The
3D mode offers much improved sensitivity, but data are
affected much more by scattered events. Scatter correction
methods differ between PET vendors and system models,
and quantitative biases in SUVR calculations due to
different or incorrect scatter correction have been reported
[92,93]. Moreover, correction is not uniform, for example,
differing between inferior planes encompassing the
cerebellum and superior planes encompassing cortical
regions. Because of this phenomenon, consistent patient
positioning in the axial center of the scanner field of view
(FOV) is important for minimizing longitudinal variability
due to scatter correction differences.4.4. Reconstruction methods
The most common reconstruction methods are FBP or
OSEM. More recent scanners offer methods to further
improve signal to noise using time of flight (ToF) or spatial
resolution using resolution recovery techniques incorpo-
rating a spatially variant point spread function. Iterative
techniques have become the standard for qualitative visual
analysis because of their improved noise properties over
FBP. Likewise, iterative techniques have been used in
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lished recently. Doot et al. [94] has found relatively small
differences due to analytical and iterative techniques in
quantitative analysis of phantom data, provided smoothing
levels were matched and a reasonably large number of iter-
ations and subjects were used to ensure algorithm conver-
gence. Resolution recovery and ToF techniques are
relatively new, not available on all scanners, and the poten-
tial improvement on amyloid imaging is not fully understood
at this point, so these methods are not currently implemented
in a multicenter clinical study.4.5. Scanner field of view, sensitivity, and noise equivalent
counts
Axial FOVs for modern PET scanners range from approx-
imately 140 mm to .200 mm. Scanners with shorter axial
FOV run the risk of subjects not being positioned well, re-
sulting in truncation of the inferior portions of the brain
such as cerebellum, or inclusion in the noisy planes at the
edge of the FOV. Scanners with longer axial FOVs offer ad-
vantages in two ways for amyloid imaging. First, the overall
scanner sensitivity is increased because of the increased
number of crossdetector planes in a 3D acquisition. Second,
most subjects can be positioned so that important reference
regions such as the cerebellum are not imaged in the outer
planes, where sensitivity is lowest.
Overall sensitivity is another scanner property that could
cause measurement variability. Ideally, an imaging protocol
could be designed to obtain equivalent counts from scanners
with low sensitivity by increasing acquisition time. Howev-
er, scanner sensitivities can differ by more than a factor of
two, making it impractical to harmonize scanner sensitiv-
ities. Although some studies have shown no quantitative
bias in SUVR for low versus high statistics amyloid acquisi-
tions [53,61], the observations that SUV estimates of FDG
uptake tend to increase with decreased signal noise [95]
and that visual analyses are qualitatively more difficult to
assess with more noise could be adequate reasons for reject-
ing a scanner in a clinical trial with a small axial FOVor low
sensitivity.4.6. Scanner qualification and QC issues
Current best practice for PET imaging QC in a multi-
center study requires acquisition and analysis of a phantom
data set at each imaging center before the start of the study as
a qualification step to verify adequate image uniformity,
signal to noise, and sensitivity. The phantom scans are also
used to calibrate the spatial resolution properties of the scan-
ner. Throughout the course of a trial, scanner quality must be
maintained, and this is generally achievable through
manufacturer-recommended daily QC. Long-term global
drifts in scanner sensitivity are not likely to affect SUVR
measurements as any change should apply uniformly to
target and reference regions. More important are QC issuesthat could regionally change scanner sensitivity or unifor-
mity, such as streak artifacts caused by bad detector blocks
or axial nonuniformities due to normalization errors. A
detailed description of QC procedures is beyond the scope
of this document, but daily automated and visual checks of
these issues at the site and central core laboratory checks
for these issues as data are collected are crucial to maintain-
ing high-quality data. Scanner upgrades or hardware repairs
may require requalification to verify that the scanner is per-
forming according to the recorded baseline performance.
It is highly advisable to acquire all longitudinal scans for
a subject using the same scanner, with the same acquisition
and reconstruction parameters, because longitudinal follow-
up using a different scanner can introduce substantial vari-
ability in SUVR measures. In general, differences between
scanners within the same vendor are less than differences be-
tween vendors due to software differences; however, before
allowing longitudinal data acquired from any form of
different scanner vendor or model, a phantom validation
study should be done to evaluate differences. Unfortunately,
very little data exist to estimate the potential SUVR vari-
ability likely to be induced by a scanner change. The
approach using Hoffman phantom data to calibrate for
spatial resolution differences has been adopted by ADNI
and many pharmaceutical studies; however, the authors of
this technique acknowledge that modeling differences due
to scatter, attenuation correction, and differing brain sizes
is difficult and that it may not be possible to calibrate scanner
differences using phantom data alone [78]. In most cases, it
is likely that correction factors cannot be found to compen-
sate for all differences between different scanners used on
the same subject, and additional scans should not be
collected for a subject in an intervention trial after a scanner
change.5. Image processing and analysis factors
Transforming reconstructed PET image data to a quanti-
tative measure of amyloid burden involves several steps, and
each of these can significantly affect the values derived from
the image. The first step is a QC inspection of the image files
to identify issues that may have arisen during acquisition.
This is followed by image transformation and measurement,
where QC of the results of the various image postprocessing
steps is also essential. Because the final values are so contin-
gent on the methods used, all the steps followed and software
used should be described to ensure the reproducibility and
reliability of the results.6. Image QC factors
A summary of quality issues that can be used as the basis
of data QC is presented in Table 2. Verification of compli-
ancewith the acquisition protocol can be checked by review-
ing information reported in the “header” file. This file is
attached to the image file and contains data fields identifying
Table 2
PET image quality control checks
Category Quality item
Protocol adherence Injected dose
Injected volume
Scan initiation time after injection
Scan duration
Emission acquisition (3D vs. 2D)
Number of time frames
Duration of each frame
Transmission scan performed before or after emission scan




Reconstruction parameters per protocol (method, iterations if OSEM, filtering, other)
Subject positioning and
motion
Anatomic inclusion (complete cerebellum, top of head)
Immersion in noise at edge of scanner axial field of view
Interframe motion
Motion between emission and transmission scan
Adequate counts
Image processing Consistent orientation (including left-right designation) for all scans
Proper alignment between PET scans of different time points
Proper alignment of MRI to PET scan (when MRI available for transformation to template space or transformation of VOIs to
native scan)
Goodness of fit between spatially normalized scan and template
Image analysis Fit of VOIs on subject scan
Consistency in boundary definition of VOIs and reference region across subjects
If adjustment made for tissue truncation from scanner FOV, consistency in use of adjusted VOI or reference region for all scans
within subject
Consistency across SUVRs obtained using different reference regions
Longitudinal stability of the SUVRs of regions not expected to accumulate amyloid (e.g., pons, subcortical white matter)
Abbreviations: PET, positron emission tomography; DICOM, Digital Imaging and Communication in Medicine; OSEM, ordered-subsets expectation maxi-
mization; MRI, magnetic resonance imaging; FOV, field of view.
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compliance with predefined acceptable values. The format
most commonly used in clinical trials is Digital Imaging
and Communication in Medicine (DICOM). The output
data from some scanners are in a proprietary format that
must be converted to DICOM, and these files may not
include details from the original header file that must be ob-
tained from the imaging site. Proper image orientation
including left-right convention should be verified and cor-
rected if necessary, as this will affect subsequent processing
and measurement.
Visual inspection by an expert can reveal a number of
possible issues [96]. Incomplete brain volumes due to posi-
tioning of the subject at the edge or out of the FOV can be
identified. This most frequently occurs in the inferior slices
and is found in approximately 4% of ADNI PiB scans. This
can hamper reliable measurement, especially if the reference
region used for SUVR calculation is cerebellar gray matter.
The reconstructed emission images will preferably have
been provided as subdivisions of the entire scan, commonly
in 5-minute blocks or frames. Subject motion can be evalu-
ated by comparing the head position from frame to frame,
and the amount of translation and rotation can be calculated.
Although the frames can be realigned, excessive movement
may indicate that significant motion-related noise isembedded within the frame. Selected frames may be
removed although resulting in a tradeoff between signal
reduction and retained noise. Possible misalignment be-
tween the emission and transmission scan should also be
checked by looking for asymmetry in the periphery and skull
in the attenuation-corrected image. Unless data are available
for re-reconstruction, this noise is embedded in the image
and a likely reason for exclusion. Aligned frames with
adequate subject stability are then summed or averaged
into a single scan for further processing. To manage the vol-
ume of larger studies, automated software can be used to
automate much of the image QC. The software can also be
used to generate an audit trail as part of 21 CFR Part 11
compliance.7. Image transformation factors
Registering or aligning images is necessary when more
than one scan has been acquired from a subject and measure-
ments need to be standardized across different sample times
and when images from different modalities, such as PETand
MRI, are used together. Spatial normalization, whereby im-
age data from a subject are mapped to a reference brain
space or atlas or a mathematic transformation, is calculated
to map the reference atlas to each individual image, allows
M.E. Schmidt et al. / Alzheimer’s & Dementia 11 (2015) 1050-10681062the same sampling method such as ROIs to be used across
subjects and across studies, and allows development of auto-
mated analysis pipelines. A number of tools have been
developed for registration and mapping and will generate
different results [97–99]. For example, an adaptive
PET-based alignment approach has been shown to result in
more consistent fitting of the cerebellum reference region
than a version of SPM MR-based spatial normalization
[99]. A comparison of different spatial normalization soft-
ware packages showed varying degrees of fit or overlap
with predefined anatomic regions, and this metric was
used to rank tool performance [97]. Registration can fail or
alignment errors occur when brain slices are missing or
signal occurs outside the brain. In all cases, verification of
alignment and proper fit of ROIs through visual inspection,
which can be further aided through automated detection of
out-of-range values, is critical, and method selection will
impact SUVRs.8. Measurement region selection and definition factors
8.1. Reference region selection
One of the most critical factors affecting amyloid mea-
surement is the reference region. The normalization of all
ROIs to this reference to obtain SUVRs means that vari-
ability in this region will impact all other measures for the
scan. For example, a low reference region value due to arti-
fact can result in a high SUVR value and falsely elevated es-
timate of amyloid burden. In longitudinal studies, where
changes in amyloid burden may be modest, variability in
the reference region signal measurement can generate signif-
icant shifts in the SUVR value. If unaddressed, the sensi-
tivity of SUVR-based analyses may be reduced leading to
erroneous conclusions regarding disease progression treat-
ment effect.
Selection of the reference region can depend on a number
of considerations including the tracer used, comparison with
other studies, reliability in region delineation, and the sub-
jects to be studied. The cerebellar cortex was selected for
the first clinical studies with 11C-PiB PET because of its re-
ported lack of Congo red and thioflavin-S–stained plaques
[100–102], presumed stability over time, and because
clearance of the tracer from cerebellar gray is more
similar to its clearance from the cerebral gray matter
target regions than from white matter [52]. As noted previ-
ously, cerebellar gray ROIs are highly vulnerable to noise
due to its low signal level, proximity to the edge of the scan-
ner FOV where noise and truncation can occur, influence by
scatter, and susceptibility to intrusion of higher white cere-
bellar signal or lower CSF signal into region boundaries if
subject motion occurs. Cerebellar cortex may also accumu-
late plaques in late-stage disease [103] and in presenilin 1
mutation carriers [104]. Whole cerebellum has been used
as a reference for florbetapir scans [1,61] and by including
white matter may have higher signal intensity, lesssusceptibility to noise, and may include tissue less
vulnerable to edge and truncation effects. Whole
cerebellum is the preferred reference method for the
Centiloid project (see the following section). However, the
whole cerebellum can still be affected by the variability of
cerebellar gray. The pons (and/or brainstem), which has
high retention of tracer as a white matter structure but is
devoid of amyloid deposits until very late-stage disease
[37], has been used in analysis of flutemetamol scans
[105]. Advantages of the pons include higher signal, less
vulnerability to edge noise and truncation, and superior sta-
tistical power in some comparisons. The initial delivery of
tracer to the pons measured in dynamic flutemetamol scans
is very similar to cerebellar gray matter and much higher
than the white matter region centrum semiovale, suggesting
more comparable blood flow [105]. However, the pons can
introduce variability because of its small volume and sensi-
tivity to head motion. Subcortical white matter does not
accumulate amyloid [31], and the centrum semiovale has
been used as a reference region [44]. Such a region could
have technical advantages by being located in the same
plane as cortical target regions and therefore less susceptible
to differences in scatter correction between superior and
inferior planes. Nonetheless, delineation of the region has
not been standardized and has not been commonly used.
Furthermore, just as there can be spillover of signal from
white matter into gray matter regions, cortical signal can
spillover into adjacent white matter, confounding precise
assignment of the measured signal to a particular tissue
type. Combinations of reference regions including pons,
whole cerebellum, and subcortical white matter have been
proposed to offset individual region variability although
formal comparisons in performance of these different refer-
ence regions in longitudinal studies have not yet been
published.8.2. Regions of interest
Selecting the regions of the brain for analysis is critical and
depends on the hypotheses being testing. There are many
methods for defining brain regions, including both manual
and automated methods. These are discussed in further detail
in the Supplementary Material. Studies have typically evalu-
ated amyloid burden using cortical frontal, lateral temporal,
lateral parietal, anterior cingulate, and posterior cingulate/pre-
cuneus regions, based on findings that these regions show the
greatest tracer retention in AD patients relative to normal con-
trols [106,107] and consistent with pathologic studies of
amyloid accumulation [37,101]. A cortical average SUVR
is often calculated using these regions for a simplified
measure. Occipital cortex is sometimes included [108] but
can add variance because of heterogeneity in amyloid accu-
mulation [106] and possible association with CAA [28]. As
clinical trials move into earlier disease stages, specific regions
may provide a more sensitive measure than a cortical average
[109,110].
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anatomic region included for measurement (entire structure
vs. most amyloid vulnerable subregions) and methods to
reduce the influence of atrophy and white matter spillover.
One approach is to erode the boundaries of each ROI from
neighboring tissue [111], which can be done in combination
with individualized gray segment masking. This may be a
less variable though approximate approach than PVE correc-
tion, which is highly method dependent [82].9. Standardization factors
9.1. Amyloid threshold selection
The definition of amyloid positivity as a single cutoff value
(such as 1.5 for 11C-PiB) has been appealing to characterize
diagnostic groups [112] and provide a basis for individual
enrollment in a clinical trial or analysis. However, the rele-
vance of a cutoff depends on the tracer, image acquisition
and analysis methods, population discrimination approach,
and clinical objective. Thresholds have been proposed based
on ROC separation between diagnostic groups [113], compar-
isonwith autopsy findings [1], and use of healthy young adults
to define an amyloid-negative standard [10].
9.2. Reconciliation across measurement methods
Differences in tracer binding properties, choice of uptake
units, and measurement methodologies result in different
metrics and thresholds for quantification of tracer retention.
The desire to be able to compare amyloid retention across
studies and tracers has created a need for standardization
of tracer retention in the brain. It was proposed at the 2012
Alzheimer’s Association International Conference that
quantitative amyloid imaging metrics could be standardized
by fitting the outcome of each tracer/analysis method to a
scale with units from zero to 100 called “centiloids.” The
Centiloid Project working group will establish a PiB PET
reference scale using standard analysis of PiB scans per-
formed on two groups to define the scale anchor points: a
group of healthy control subjects aged ,45 years (who
should have no amyloid) as the lower anchor (zero point)
for the scale and typical AD patients whose mean SUVR
value will define the upper anchor (100 points) for the scale.
The second phase of the project outlines a method for subse-
quently scaling any alternate method of PiB analysis or any
other tracer and associated analysis method to this scale. To
allow research laboratories to map their data and methods to
the reference Centiloid scale, a set of PET and MRI scans
along with details of the analysis methods used by the work-
ing group will be made available on a publically accessible
server [114].10. Discussion
Amyloid PET has the potential to significantly assist the
development of disease-modifying treatments for AD.Quantitative measurement of amyloid PET, if sufficiently
sensitive and reliable, can be used to confirm that treatments
targeting fibrillar Ab are able to get into the brain, are able to
fulfill their mechanism of action, and can help define clini-
cally relevant and safe doses. Tremendous strides in devel-
oping quantitative measurement of amyloid PET have
been made by ADNI and related research consortia, imaging
companies, and academic laboratories. The first standard-
ized protocols, guidance on image QC, and analysis methods
owe their existence to these efforts. Nonetheless, for quanti-
tative amyloid PET to be robust and reliable, these have to be
regarded as foundational and not final steps. The ongoing
testing of methods for CSF biomarkers and volumetric
MRI illustrate the work necessary to reduce variability due
to measurement error and noise and support their qualifica-
tion by health authorities as biomarkers of disease progres-
sion [115-117]. Similar efforts for quantitative PET are
needed.
As we have outlined, numerous factors impact the values
derived from amyloid PET and can be a source of measure-
ment error. We have summarized those we regard as key fac-
tors, how they can impact data quality, and mitigation
strategies in a table in the Supplementary Material and high-
light them here.
Several biological factors influence the incidence and
interpretation of the amyloid PET signal although most are
primarily relevant for study design and subject selection/
stratification. Impact on longitudinal change in amyloid
PET signal once factors such as age, genetic background,
comorbid conditions have been controlled is minimal,
although effects on tracer distribution by drug-drug interac-
tion and blood flow remain. Of these, blood flow is poten-
tially the more variable and is best addressed through how
the data are acquired; namely, the collection of dynamic
versus late emission “static” scans. The lengthy time
required for acquiring dynamic data renders this impractical
for multisite phase 2 and 3 trials; however, dynamic scans
could be considered for focused, proof-of-principle phase
2 studies conducted at a limited number of research sites.
The most critical family of factors is acquisition. For reli-
able quantitative amyloid PET data, good-quality acquisi-
tion is essential and this begins with how sites are selected
and qualified and should include phantom testing and critical
review of phantom data. Once qualified, sites need to
demonstrate accurate and sensitive scanner performance
and provide evidence of regular equipment QC to ensure
data consistency. Examples of this include the standardiza-
tion for FDG PET by QIBA and the site accreditation pro-
gram developed for FDG PET/CT in cancer trials by the
EANM Research Ltd [4,90]. The latter program includes a
mechanism for site accreditation, standards for phantom
testing, and direction for quarterly calibration QC testing
and annual image QC testing, and accreditation is
maintained by continuing to meet specifications. A critical
lesson of standardization efforts by QIBA and the EANM
is that defining best practices for quantitative imaging is a
M.E. Schmidt et al. / Alzheimer’s & Dementia 11 (2015) 1050-10681064precompetitive effort that allows engagement of imaging
service providers, academic experts in imaging, and
customers. As we have learned in ADNI, such efforts are
beyond the reach of a single company and benefit from the
collaboration of partners. Proprietary solutions may not be
in anyone’s interest, whereas shared investment may
provide funds for methods work and testing that might
otherwise not be done. Thus, next steps for optimizing
quantitative amyloid PET could include outlining the
scope, governance, and processes for reviewing topics
such as site qualification, QC, and acquisition protocols to
support standardizing.
Subject positioning in the scanner and subject movement
are major and common sources of error. Some of the
methods for head restraint may work well; others may exac-
erbate movement because of discomfort or excessive re-
straint. Determining the optimal approach could be easily
tested by having subjects lay in the scanner with the different
restraint methods and tracking movements under each
method with a video camera. In the event that movement
does occur, having software for registering emission frames
with the transmission scan before reconstruction could
reduce error due to embedded transmission/emission
misregistration. Because transmission/emission motion
correction needs to be carried out in projection space before
reconstruction and because reconstruction implementations
are not openly available and vary widely between scanners,
this most likely needs to be a vendor-driven fix.
For image analysis, fundamental questions remain
around the reference region. The optimal reference region
may differ between cross-sectional studies, where differ-
ences between subjects are the focus, and longitudinal
studies, where subtle differences within subjects are the
end point. Cerebellar gray matter performs well for distin-
guishing between healthy subjects and those with AD or at
risk and may be an acceptable reference tissue for many
studies. However, the vulnerability of this region to accumu-
lation of amyloid in mutations carriers and late-stage AD, its
position close to the edge of the FOV, intrinsically low signal
and errors in scatter correction, and potential errors in seg-
mentation and coregistration may not make this the best re-
gion for longitudinal studies. Systematic comparison and
analysis of within-subject variability using different refer-
ence regions such as whole cerebellum, pons, and subcor-
tical white matter are needed. Ideally, these analyses
should include at least three time points to allow detection
of implausible trajectories (e.g., decreases followed by in-
creases in excess of test-retest variability) and determining
whether an alternative reference region reduces within-
subject variability. PVE correction is another question that
bedevils image analysis in AD and could also benefit from
more systematic comparisons in longitudinal data sets. To
resolve these questions, publically available image data
sets such as ADNI are essential. Such data sets allow
head-to-head comparison of methods and use of healthy con-
trol data as reference. This is planned to be a feature of theCentiloid project and is an argument for making image
data from intervention trials available, such as amyloid
PET scans acquired on placebo-treated subjects.
With the movement in intervention trials to earlier
stages of disease, such as the Anti-Amyloid treatment in
Asymptomatic Alzheimer’s (A4) study (http://a4study.
org/), it is time to revisit threshold values for amyloid
burden that were established for discriminating between
AD and healthy subjects. Lower or region-specific cutoffs
may be appropriate for studies designed to enroll subjects
very early in disease course, determine whether there is suf-
ficient amyloid to detect removal, or to evaluate
“emerging” subjects who may initially have one amyloid-
positive region rather than a positive cortical average
SUVR. Questions such as these can benefit from histology
data from autopsies of subjects with antemortem amyloid
PET scans as “ground truth,” and we encourage companies
and research groups to include autopsy protocols and con-
sents in trials whenever possible. It is also important to
ensure industry awareness that SUVR values used to deter-
mine trial inclusion or to support diagnosis, depends on the
tracer, acquisition protocol, and processing methods that
were used to generate the value.
Finally, acquisition and reconstruction protocols, missing
or censored data including QC thresholds for exclusion, im-
age analysis software, scanner or scanner software changes
over the course of the study, and statistical analysis plans
should be fully reported to allow for reproducing the results
of a study, consonant with the emerging publishing standards
for reproducible research.
These recommendations are for the immediate and near
future of quantitative amyloid imaging in support of research
in AD and related dementias. Future methods will likely
include ligands for tau, inflammation markers, and func-
tional measures, and each of these methods will confront
the same issues regarding variability of data collected in
multisite studies over time. Developing a robust approach
to quantitative measurement of tau PET may be especially
important, as autopsy data suggest that the signal distribu-
tion may evince more regionally distinct patterns than amy-
loid PET [118]. It is our hope that developing best practices
for quantitative amyloid PET may provide a pathway for
optimizing these newer methods as they too are adopted as
clinical research tools.Acknowledgments
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